Search alternatives:
significant treatment » significant investment (Expand Search), significant enrichment (Expand Search), significant impairment (Expand Search)
treatment decrease » treatment decreased (Expand Search), treatments decreased (Expand Search), treatment increases (Expand Search)
small decrease » small increased (Expand Search)
fold decrease » fold increase (Expand Search), fold increased (Expand Search), fold increases (Expand Search)
significant treatment » significant investment (Expand Search), significant enrichment (Expand Search), significant impairment (Expand Search)
treatment decrease » treatment decreased (Expand Search), treatments decreased (Expand Search), treatment increases (Expand Search)
small decrease » small increased (Expand Search)
fold decrease » fold increase (Expand Search), fold increased (Expand Search), fold increases (Expand Search)
-
1
Decreased clonogenic capacity of U87MG and U251MG GB cells following treatment with SHG-44 and cis-platin at equal concentrations.
Published 2025“…<b>(B-C)</b> Microscopic imaging confirmed the inhibition of colony formation in U87MG cells following SHG-44 treatment, with no colonies evident. <b>(D)</b> Similarly, U251MG cells showed significantly decreased clonogenic potential upon 100ΜM SHG-44 treatment when compared to 100ΜM cis-platin and the untreated control. …”
-
2
-
3
Decreased clonogenic capacity of U87MG and U251MG glioma cells dependent on SHG-44 concentration.
Published 2025“…<p><b>(A)</b> A significant decrease in the proliferative clonal capacity of U87MG colonies was observed with 70ΜM and 100ΜM SHG-44 treatment. …”
-
4
-
5
-
6
Identification of ACADM, ANGPTL4, and NFKB2 as significant predictors of OS in the TCGA-KIRC cohort.
Published 2025Subjects: -
7
-
8
-
9
MiR-129-5p levels were decreased in mouse depression models.
Published 2025“…The Y-axis represents the fold change, while the X-axis indicates the significance of differential expression. …”
-
10
-
11
-
12
-
13
Change in Watt’s Connectedness Scale (WCS), General Connectedness by Treatment Group.
Published 2025Subjects: -
14
-
15
-
16
-
17
Baseline demographics and comorbidities by presence of post-treatment adverse cardiovascular events.
Published 2024Subjects: -
18
-
19
-
20